Hemogenyx Pharmaceuticals Cash Flow Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-9.76	-5.62	-6.69	-3.98	-5.1
Depreciation & Amortization	0.59	0.64	0.65	0.2	0.13
Loss (Gain) From Sale of Assets	0	-	-	-	-
Asset Writedown & Restructuring Costs	0.27	-	-	-	-
Stock-Based Compensation	0.06	0.34	0.24	0.02	0.15
Other Operating Activities	4.64	-0.11	0.53	0.61	2.09
Change in Accounts Receivable	-0.01	-0	0	-0	-0.2
Change in Accounts Payable	0.43	0.35	0.03	-0.03	0.3
Change in Other Net Operating Assets	0.33	0.26	-0.87	0.27	-
Operating Cash Flow	-3.45	-4.14	-6.11	-2.91	-2.63
Capital Expenditures	-0	-0.01	-0.12	-0.43	-0.64
Sale (Purchase) of Intangibles	-	-	-	-	-0.18
Other Investing Activities	-0	0.01	0.09	0.01	-0.12
Investing Cash Flow	-0.01	-0	-0.03	-0.42	-0.94
Long-Term Debt Repaid	-0.63	-0.64	-0.64	-0.11	-3.22
Net Debt Issued (Repaid)	-0.63	-0.64	-0.64	-0.11	-3.22
Issuance of Common Stock	5.52	3.93	5.25	-	12
Other Financing Activities	-	-0.21	-0.17	-	-
Financing Cash Flow	4.89	3.08	4.45	-0.11	8.78
Foreign Exchange Rate Adjustments	-0.01	-0.02	0.4	-0.88	-0.18
Miscellaneous Cash Flow Adjustments	-	-	-	0.01	-
Net Cash Flow	1.43	-1.09	-1.29	-4.31	5.03
Free Cash Flow	-3.45	-4.15	-6.22	-3.34	-3.26
Free Cash Flow Per Share	-0.60	-1.26	-2.20	-1.36	-1.69
Levered Free Cash Flow	-3.39	-1.96	-4.37	-3.35	-3.11
Unlevered Free Cash Flow	-3.25	-1.79	-4.18	-3.35	-2.24
Change in Working Capital	0.75	0.6	-0.83	0.24	0.1

Source: S&P Global Market Intelligence. Standard template. Financial Sources.